{"name":"Aclaris Therapeutics","slug":"aclaris-therapeutics","ticker":"ACRS","exchange":"NASDAQ","domain":"aclaristx.com","description":"Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various di","hq":"Wayne, PA","founded":0,"employees":"69","ceo":"","sector":"Autoimmune / Dermatology / Oncology","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":4.89,"stockChange":-0.2,"stockChangePercent":-3.93,"marketCap":"$684M","metrics":{"revenue":8367000,"revenueGrowth":37.2,"grossMargin":0,"rdSpend":0,"netIncome":-69662000,"cash":105416000,"dividendYield":0,"peRatio":-6.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"oncology","drugs":[{"name":"A-101 40%","genericName":"A-101 40%","slug":"a-101-40","indication":"Other","status":"phase_1"},{"name":"A-101 Solution 40","genericName":"A-101 Solution 40","slug":"a-101-solution-40","indication":"Treatment of primary axillary hyperhidrosis","status":"phase_2"},{"name":"A-101 Topical Solution","genericName":"A-101 Topical Solution","slug":"a-101-topical-solution","indication":"Other","status":"marketed"},{"name":"A-101 Topical Solution 40%","genericName":"A-101 Topical Solution 40%","slug":"a-101-topical-solution-40","indication":"Treatment of primary axillary hyperhidrosis","status":"phase_2"},{"name":"ATI-2138","genericName":"ATI-2138","slug":"ati-2138","indication":"Other","status":"phase_2"},{"name":"ATI-502","genericName":"ATI-502","slug":"ati-502","indication":"Treatment of essential tremor","status":"phase_2"},{"name":"A-101 25%","genericName":"A-101 25%","slug":"a-101-25","indication":"Other","status":"phase_1"},{"name":"A-101 32.5%","genericName":"A-101 32.5%","slug":"a-101-32-5","indication":"Other","status":"phase_1"},{"name":"A-101 Solution","genericName":"A-101 Solution","slug":"a-101-solution","indication":"Seborrheic keratosis","status":"phase_3"},{"name":"A-101 Solution 45","genericName":"A-101 Solution 45","slug":"a-101-solution-45","indication":"Seborrheic keratosis","status":"phase_2"},{"name":"ATI-50002","genericName":"ATI-50002","slug":"ati-50002","indication":"Other","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"ATI-045","genericName":"ATI-045","slug":"ati-045","indication":"Moderate to severe atopic dermatitis","status":"phase_2"},{"name":"ATI-1777","genericName":"ATI-1777","slug":"ati-1777","indication":"Moderate to severe atopic dermatitis","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ATI-50002 topical solution","genericName":"ATI-50002 topical solution","slug":"ati-50002-topical-solution","indication":"Moderate to severe plaque psoriasis","status":"phase_2"}]}],"pipeline":[{"name":"A-101 40%","genericName":"A-101 40%","slug":"a-101-40","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A-101 Solution 40","genericName":"A-101 Solution 40","slug":"a-101-solution-40","phase":"phase_2","mechanism":"A-101 Solution 40 is a topical solution used to treat hyperhidrosis.","indications":["Treatment of primary axillary hyperhidrosis"],"catalyst":""},{"name":"A-101 Topical Solution","genericName":"A-101 Topical Solution","slug":"a-101-topical-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A-101 Topical Solution 40%","genericName":"A-101 Topical Solution 40%","slug":"a-101-topical-solution-40","phase":"phase_2","mechanism":"A-101 Topical Solution 40% is a topical solution used to treat hyperhidrosis.","indications":["Treatment of primary axillary hyperhidrosis"],"catalyst":""},{"name":"ATI-045","genericName":"ATI-045","slug":"ati-045","phase":"phase_2","mechanism":"ATI-045 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"ATI-1777","genericName":"ATI-1777","slug":"ati-1777","phase":"phase_2","mechanism":"ATI-1777 is a small molecule inhibitor of the JAK1 and JAK2 enzymes.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"ATI-2138","genericName":"ATI-2138","slug":"ati-2138","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATI-502","genericName":"ATI-502","slug":"ati-502","phase":"phase_2","mechanism":"ATI-502 is a small molecule inhibitor of the serotonin receptor 5-HT2A.","indications":["Treatment of essential tremor"],"catalyst":""},{"name":"A-101 25%","genericName":"A-101 25%","slug":"a-101-25","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A-101 32.5%","genericName":"A-101 32.5%","slug":"a-101-32-5","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A-101 Solution","genericName":"A-101 Solution","slug":"a-101-solution","phase":"phase_3","mechanism":"A-101 is a topical solution that induces controlled necrosis of skin lesions through a proprietary mechanism.","indications":["Seborrheic keratosis","Common warts","Molluscum contagiosum"],"catalyst":""},{"name":"A-101 Solution 45","genericName":"A-101 Solution 45","slug":"a-101-solution-45","phase":"phase_2","mechanism":"A-101 Solution 45 is a topical keratolytic agent that chemically destroys skin lesions through controlled application of a caustic formulation.","indications":["Seborrheic keratosis","Actinic keratosis"],"catalyst":""},{"name":"ATI-50002","genericName":"ATI-50002","slug":"ati-50002","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATI-50002 topical solution","genericName":"ATI-50002 topical solution","slug":"ati-50002-topical-solution","phase":"phase_2","mechanism":"ATI-50002 topical solution is a small molecule that targets the Janus kinase (JAK) pathway.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":14,"phaseCounts":{"phase_1":3,"phase_2":9,"marketed":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":7826000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":7826000},{"period":"2024-12-31","value":18720000},{"period":"2023-12-31","value":31249000},{"period":"2022-12-31","value":29752000}],"grossProfit":542000,"grossProfitHistory":[{"period":"2025-12-31","value":542000},{"period":"2024-12-31","value":3262000},{"period":"2023-12-31","value":13168000},{"period":"2022-12-31","value":17792000}],"rdSpend":52645000,"rdSpendHistory":[{"period":"2025-12-31","value":52645000},{"period":"2024-12-31","value":33586000},{"period":"2023-12-31","value":98384000},{"period":"2022-12-31","value":77813000}],"sgaSpend":21972000,"operatingIncome":-70260000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-70260000},{"period":"2024-12-31","value":-50613000},{"period":"2023-12-31","value":-116314000},{"period":"2022-12-31","value":-85154000}],"netIncome":-64923000,"netIncomeHistory":[{"period":"2025-12-31","value":-64923000},{"period":"2024-12-31","value":-132065000},{"period":"2023-12-31","value":-88481000},{"period":"2022-12-31","value":-86908000}],"eps":-1.71,"epsHistory":[{"period":"2024-12-31","value":-1.71},{"period":"2023-12-31","value":-1.27},{"period":"2022-12-31","value":-1.33},{"period":"2021-12-31","value":-1.6}],"cash":19960000,"cashHistory":[{"period":"2025-12-31","value":19960000},{"period":"2024-12-31","value":24570000},{"period":"2023-12-31","value":39878000},{"period":"2022-12-31","value":45277000}],"totalAssets":160460000,"totalLiabilities":57378000,"totalDebt":426000,"equity":103082000,"operatingCashflow":-47113000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-47113000},{"period":"2024-12-31","value":-20075000},{"period":"2023-12-31","value":-78325000},{"period":"2022-12-31","value":-67567000}],"capex":-111000,"capexHistory":[{"period":"2025-12-31","value":-111000},{"period":"2024-12-31","value":-35931000},{"period":"2023-12-31","value":-1309000},{"period":"2022-12-31","value":-605000}],"freeCashflow":-47224000,"dividendsPaid":null,"buybacks":null,"employees":69,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":5576000,"ebit":-21029000,"ebitda":-20927000,"period":"2025-12-31","revenue":1295000,"epsBasic":-0.16,"netIncome":-19795000,"rdExpense":16584000,"epsDiluted":-0.16,"grossProfit":-174000,"operatingIncome":-21029000},{"sga":4871000,"ebit":-16333000,"ebitda":-16223000,"period":"2025-09-30","revenue":3299000,"epsBasic":-0.12,"netIncome":-14614000,"rdExpense":13028000,"epsDiluted":-0.12,"grossProfit":850000,"operatingIncome":-16333000},{"sga":5386000,"ebit":-15947000,"ebitda":-15833000,"period":"2025-06-30","revenue":1777000,"epsBasic":-0.13,"netIncome":-15429000,"rdExpense":11449000,"epsDiluted":-0.13,"grossProfit":-73000,"operatingIncome":-15947000},{"sga":6139000,"ebit":-16951000,"ebitda":-16823000,"period":"2025-03-31","revenue":1455000,"epsBasic":-0.12,"netIncome":-15085000,"rdExpense":11584000,"epsDiluted":-0.12,"grossProfit":-61000,"operatingIncome":-16951000},{"sga":4954000,"ebit":-12156000,"ebitda":-12013000,"period":"2024-12-31","revenue":9211000,"epsBasic":-1.01,"netIncome":-96552000,"rdExpense":9026000,"epsDiluted":-1.01,"grossProfit":-90000,"operatingIncome":-12156000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.89,"previousClose":5.09,"fiftyTwoWeekHigh":5.15,"fiftyTwoWeekLow":1.16,"fiftyTwoWeekRange":"1.16 - 5.15","fiftyDayAverage":4.01,"twoHundredDayAverage":2.9,"beta":0.78,"enterpriseValue":607457152,"forwardPE":-6.8,"priceToBook":4.76,"priceToSales":81.71,"enterpriseToRevenue":72.6,"enterpriseToEbitda":-7.74,"pegRatio":0,"ebitda":-78469000,"ebitdaMargin":0,"freeCashflow":-32210876,"operatingCashflow":-52205000,"totalDebt":1985000,"debtToEquity":1.4,"currentRatio":4.03,"returnOnAssets":-24.7,"returnOnEquity":-48.4,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":9,"targetMeanPrice":9.67,"targetHighPrice":16,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.2,"institutionHeldPercent":73.8,"sharesOutstanding":139663680,"floatShares":96690562,"sharesShort":7889202,"shortRatio":5.46,"shortPercentOfFloat":5.7,"epsTrailing":-0.56,"epsForward":-0.72,"revenuePerShare":0.07,"bookValue":1.03,"officers":[{"age":55,"name":"Dr. Neal S. Walker D.O., M.D.","title":"Co-Founder, CEO & Chairman"},{"age":65,"name":"Dr. Hugh M.  Davis Ph.D.","title":"President, COO & Director"},{"age":38,"name":"Mr. Kevin  Balthaser","title":"Chief Financial Officer"},{"age":60,"name":"Mr. James  Loerop","title":"Chief Business Officer"},{"age":61,"name":"Dr. Roland  Kolbeck Ph.D.","title":"Chief Scientific Officer"},{"age":56,"name":"Mr. William C. Roberts","title":"Senior Vice President of Corporate Communications & Investor Relations"},{"age":null,"name":"Mr. Matthew  Rothman J.D.","title":"General Counsel & Corporate Secretary"},{"age":null,"name":"Dr. Jon  Jacobsen Ph.D.","title":"Senior Vice President of Chemistry"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.aclaristx.com","phone":"484 324 7933"}}